We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt.
- Authors
Santos, Ana Belén; Llamas, Pilar; Román, Alejandro; Prieto, Elena; de Oña, Raquel; de Velasco, Jaime Fernández; Tomás, José Francisco
- Abstract
An increased incidence of deep venous thrombosis (DVT) has been described in multiple myeloma (MM). We present a MM patient who was a homozygous carrier of the C677T mutation of the MTHFR gene who developed a DVT and a pulmonary embolism (PE) during thalidomide treatment. Thalidomide is an immunomodulator that inhibits the angiogenesis induced by vascular endothelial growth factor and fibroblast growth factor, although the exact mechanism of thalidomide in MM is unknown. We report on the use of thalidomide in eight patients with significant renal failure, of whom six developed severe unexplained hyperkalaemia, a hitherto unreported side-effect of thalidomide therapy.
- Subjects
THALIDOMIDE; PEPTIDES; THROMBOSIS; CARDIOVASCULAR diseases; THERAPEUTICS; NEOVASCULARIZATION
- Publication
British Journal of Haematology, 2003, Vol 122, Issue 1, p159
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1046/j.1365-2141.2003.04395_1.x